Ress Life Investments A/S
15.9.2026 19:30:00 CEST | Globenewswire | Press release
Ress Life Investments A/S publishes Net Asset Value (NAV).
Ress Life Investments A/S publishes Net Asset Value (NAV).
Ress Life Investments
Nybrogade 12
DK-1203 Copenhagen K
Denmark
CVR nr. 33593163
www.resslifeinvestments.com
To: Nasdaq Copenhagen
Date: 15 September 2026
Corporate Announcement 30/2026
Ress Life Investments A/S publishes Net Asset Value (NAV).
Ress Life Investments A/S publishes the Net Asset Value (NAV) per share as of 31 August 2026.
NAV per share in USD: 2750.13
The performance during August is 0.62% in USD. The year-to-date net performance is 4.22% in USD.
Assets under management (AUM) are 227.7 million USD.
The NAV per share in EUR is published on the website of Nasdaq Copenhagen under the section AIF Companies and Funds, where the bid and ask prices are published. The daily NAV in EUR is calculated as the most recently published NAV in USD divided by the European Central Bank’s EUR/USD reference rate on the relevant day.
Questions related to this announcement can be made to the company's AIF-manager, Finserve Nordic AB.
Contact person:
Gustaf Hagerud
gustaf.hagerud@finserve.se
Tel + 46 73 660 72 42
Note: The terms for subscription of shares, minimum subscription amount and redemption of shares are provided in the Articles of Association, Information Brochure and in the Key Information Document available on the Company's website, www.resslifeinvestments.com.
Attachment
Documents
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Genmab A/S7.10.2026 18:17:08 CEST | Press release
Resolution Adopted at the Extraordinary General Meeting of Genmab A/S Including Grant of Restricted Stock Units to Board Members
Tilray Brands, Inc.7.10.2026 18:00:00 CEST | Press release
BrewDog’s Winning Streak Rolls on with Gold at the Scottish Beer Awards
Novartis Pharma AG7.10.2026 17:45:00 CEST | Press release
Novartis Rhapsido® (remibrutinib) receives FDA approval as first treatment for symptomatic dermographism (SD), expanding its use beyond chronic spontaneous urticaria (CSU)
Solvay S.A.7.10.2026 17:45:00 CEST | Press release
Participation notifications by SIH Partners
COMSOL, Inc7.10.2026 17:30:00 CEST | Press release
Comsol Named Official Multiphysics Partner of Formula E
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom